Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Total Revenue
889,895
751,040
548,485
500,723
Cost of Revenue
152,008
129,764
95,742
91,830
Gross Profit
737,887
621,276
452,743
408,893
Operating Expenses
Research Development
634,806
461,543
354,780
302,218
Selling General and Administrative
402,271
302,156
235,356
198,173
Non Recurring
--
--
--
--
Others
(188,488)
(49,532)
18,614
18,717
Total Operating Expenses
848,589
714,167
608,750
519,108
Operating Income or Loss
(110,702)
(92,891)
(156,007)
(110,215)
Income from Continuing Operations
Total Other Income/Expenses Net
(38,773)
(1,272)
(13,132)
(3,008)
Earnings Before Interest And Taxes
(144,974)
(88,226)
(166,056)
(110,639)
Interest Expense
9,750
36,642
10,447
7,639
Income Before Tax
(154,724)
(124,868)
(176,503)
(118,278)
Income Tax Expense
17,075
9,101
(150)
(3,931)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(171,799)
(133,969)
(176,353)
(114,347)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(171,799)
(133,969)
(176,353)
(114,347)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(171,799)
(133,969)
(176,353)
(114,347)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information